Concepedia

Author

H. Küpper

Abbott (Germany)

Also Known As

A. Strangfeld, B. Guerette, G. Patel, H KUPPER, H Kupper, H Küpper, H. J. Küpper, H. Kupper, H. Küpper, HARTMUT KUPPER

234

Publications

7.6K

Citations

40

H-Index

35

Concepts

All Affiliations

Abbott (Germany)Charité - Universitätsmedizin BerlinAbbVie (United States)AbbVie (Germany)Abbott (United States)
HK

About

H. Küpper is an author at Abbott (Germany) specializing in medicine, rheumatic diseases, and rheumatology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

874

2

Allergy

1

1

76

3

Clinical Immunology

1

1

24

4

Immunology

1

1

24

5

Neurology

1

1

154

H. Küpper

×

68

Publications

7.3K

Citations

39

H-Index

YearCitations

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial

Désirée van der Heijde, Alan Kivitz, Michael Schiff,

Arthritis & Rheumatism

2006

874

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

L.B.A. van de Putte, Michel Malaise, J Sany,

Annals of the Rheumatic Diseases

2004

617

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

Désirée van der Heijde, David Salonen, Barbara N. Weissman,

Arthritis Research & Therapy

2009

406

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve‐week randomized, double‐blind, placebo‐controlled trial followed by an open‐label extension up to week fifty‐two

Hildrun Haibel, Martín Rudwaleit, Joachim Listing,

Arthritis & Rheumatism

2008

313

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

Martín Rudwaleit, E Rødevand, Peter Holck,

Annals of the Rheumatic Diseases

2008

284

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

Josef S Smolen, Paul Emery, Roy Fleischmann,

The Lancet

2013

272

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Konrad Reinhart, T. Menges, Bengt Gårdlund,

Critical Care Medicine

2001

260

Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis

Margaret C. Reilly, Katherine Gooch, Robert Wong,

Lara D. Veeken

2010

232

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Gerd‐Rüdiger Burmester, Alan Kivitz, H. Küpper,

Annals of the Rheumatic Diseases

2014

226

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study

Arthur Kavanaugh, Roy Fleischmann, Paul Emery,

Annals of the Rheumatic Diseases

2012

219

Page 1